Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma grants inducement equity to new President and CEO Dr. Shao-Lee Lin and six employees under Nasdaq rules, signaling leadership transition and growth strategy.

SCYNEXIS grants 125,000 stock options at $0.93/share and 20,000 RSUs to new VP under Nasdaq inducement rules.

NewAmsterdam Pharma approved inducement grants totaling 50,400 options and 15,400 RSUs to five new non-executive employees under Nasdaq compliance rules.

Intellia Therapeutics grants 67,150 RSUs to 13 new employees under Nasdaq inducement rules, signaling active talent acquisition in competitive gene-editing sector.

Kura Oncology granted 153,750 stock options at $8.34/share to six new employees under Nasdaq Rule 5635(c)(4), valued at approximately $1.28 million, with standard four-year vesting.

NewAmsterdam Pharma grants 15,000 options and 3,200 RSUs to two new executives, complying with Nasdaq listing regulations.

BioCryst awards 65,850 RSUs to six new employees under Nasdaq inducement rule, vesting over four years starting March 2027.